Clinical Report: First Preclinical Development Candidate for Nucleome Therapeutics

Overview

Nucleome Therapeutics has nominated NTP464, a monoclonal antibody agonist, as its first preclinical development candidate aimed at promoting inflammation resolution. This candidate shows potential across various autoimmune and inflammatory conditions, demonstrating strong potency and selectivity in preclinical assays.

Background

The development of NTP464 represents a significant advancement in the treatment of autoimmune diseases, which often rely on immunomodulation and immunosuppression. By targeting a novel inflammation checkpoint, NTP464 may offer a new therapeutic approach that actively resolves inflammation rather than merely suppressing immune responses. This innovation could address unmet needs in conditions like rheumatoid arthritis and systemic lupus erythematosus.

Data Highlights

NTP464 demonstrated strong potency, selectivity, and developability in preclinical testing, inhibiting activation of B cells, T cells, and macrophages while promoting regulatory T cell activity.

Key Findings

• NTP464 is a first-in-class monoclonal antibody agonist targeting a novel inflammation checkpoint.
• The candidate was developed using Nucleome's proprietary Micro Capture-C platform, which maps genome interactions.
• NTP464 has shown the ability to inhibit activation of key immune cells involved in inflammation.
• The program is progressing towards IND-enabling studies, with a first-in-human study anticipated in 2027.
• This approach may transform treatment strategies for autoimmune diseases by focusing on inflammation resolution.

Clinical Implications

The nomination of NTP464 highlights the potential for new therapeutic strategies in managing autoimmune diseases. Clinicians may consider the implications of targeting inflammation resolution pathways in their treatment plans, particularly for patients with conditions that are currently difficult to manage.

Conclusion

NTP464 represents a promising advancement in the field of autoimmune and inflammatory disease treatment, with the potential to change the therapeutic landscape by focusing on the resolution of inflammation.

References

1. Nucleome Therapeutics, PR Newswire, 2024 -- Nucleome Therapeutics nominates first preclinical development candidate
2. EULAR recommendations for the management of rheumatoid arthritis, Annals of the Rheumatic Diseases, 2022 -- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
3. The ASCO Post — Lung-MAP Trial Debuts—Other Personalized Studies Will Follow
4. Ophthalmology Management — May 1
5. The ASCO Post — ASH 2020: Novel Antibody-Drug Conjugate Shows Activity in Rare, Aggressive Form of Leukemia
6. Acta Neuropathologica — Accelerated Diagnosis of Brain Lymphoma via Nanopore Sequencing of Cytology-Negative Cerebrospinal Fluid
7. Nucleome Therapeutics nominates first preclinical development candidate
8. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update | Annals of the Rheumatic Diseases
9. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis - ScienceDirect